Claudio Dansky Ullmann, MD

Doug Doerfler
President and Chief Executive Officer

Mr. Doerfler has 35+ years of vast experience in biotechnology product and company development, commercialisation and international financing. He was a founder of MaxCyte in July 1998. Previously, he was President, CEO and a Director of Immunicon Corporation. He also held various executive positions with Life Technologies, Inc. (now Thermo Fisher).

Mr. Doerfler is an active Life Sciences industry advocate, serving as Chair Emeritus of the Maryland Tech Council and on the executive committee of the Biotechnology Innovation Organization. He received his BS in finance from the University of Baltimore School of Business, and holds an Industrial Relations certificate.

Claudio Dansky Ullmann, MD

Amanda L. Murphy
Chief Financial Officer

Ms. Murphy joined MaxCyte as Chief Financial Officer in 2020. Before joining MaxCyte, Ms. Murphy, a senior equity analyst focused on the biotechnology industry, served as Managing Director of BTIG, LLC. She has specialized in gene therapy, gene editing and cell therapy for both burgeoning private and established public healthcare companies. Prior to BTIG, she was a Partner and Healthcare Analyst at William Blair & Company, focused on diagnostic services and life sciences. Previously, Ms. Murphy was a Business Analyst at Caremark and a Senior Consultant within the Strategy Consulting division at PricewaterhouseCoopers. She received a BS in biology from Boston College’s honors program, and an MBA in finance, accounting and economics from the Kellogg Graduate School of Management at Northwestern University.

Claudio Dansky Ullmann, MD

Ron Holtz
Senior Vice President and Chief Accounting Officer

Mr. Holtz joined MaxCyte in 2005. Previously, he had served as the CFO of both public and private companies. He also had previous experience with Ernst & Young LLP’s Financial Advisory Services Group. He earned an MBA in finance from the University of Maryland, a BS in mathematics from the University of Wisconsin and is a Certified Public Accountant.

Claudio Dansky Ullmann, MD

Thomas M. Ross
Executive Vice President, Global Sales and Marketing

Mr. Ross has extensive experience in commercial operations and 30+ years of successful life sciences and clinical diagnostics sales and marketing leadership. Most recently, he was SVP of Commercial Operations at OpGen. He also served as Chief Commercial Officer at Predictive BioScience and VP of North America Medical Diagnostics Sales at Qiagen/Digene Corporation. He previously held senior leadership roles in Manufacturing Operations at Life Technologies, Inc. and Cambrex. Mr. Ross holds a BA in business administration from The Citadel.

Claudio Dansky Ullmann, MD

Maher Masoud
Executive Vice President and General Counsel

Mr. Masoud has 20+ years of experience in the biopharmaceutical industry, including 15 years as an attorney and general counsel. He has served as: Assistant General Counsel and Corporate Secretary for Wellstat Management Company; co-founding partner of Rossi/ Masoud LLC; and Corporate Attorney at Human Genome Sciences, Inc. A member of the Maryland State Bar, Mr. Masoud holds a JD from Michigan State University College of Law, and a BS in cell and molecular biology genetics from the University of Maryland.

Claudio Dansky Ullmann, MD

James Brady, PhD
Senior Vice President, Technical Applications and Customer Support

Prior to joining MaxCyte in 2004, Dr. Brady was a Senior Scientist at Genetic Therapy, Inc., a Novartis subsidiary, where he worked on lentiviral-based gene therapy treatments. Previously, he worked at MetaMorphix, Inc., and was a postdoctoral fellow at the National Eye Institute of the National Institutes of Health. Dr. Brady received a BS degree in biology from the College of William and Mary, a PhD in genetics from Indiana University and an MBA from Johns Hopkins University.

Claudio Dansky Ullmann, MD

Kevin Gutshall
Vice President, Strategy and Corporate Development

With 20 years of experience serving in leadership and entrepreneurial roles, Mr. Gutshall brings extensive cell and biological therapy knowledge to his position as MaxCyte’s Vice President, Strategy and Corporate Development. Most recently, he served as MilliporeSigma’s Director of Global Corporate Business Development and Mergers and Acquisitions. Previously, Mr. Gutshall was the Head of Marketing and Business Development for the Biologics Manufacturing Platform at Sigma-Aldrich and also was Director of Marketing for Thermo Fisher Scientific’s Life Science Tools Sector. In addition, he is the co-inventor of several patents as well as the co-author of several publications and presentations.

Claudio Dansky Ullmann, MD

Sarah Haecker Meeks, PhD
Senior Vice President, Business Development

Before joining MaxCyte, Dr. Meeks served as Vice President of Business Development at Synpromics (now part of AskBio) where she established a leading market position for the company, including partnerships with leading gene therapy companies, and led broad technology education and adoption initiatives. Prior to her work at Synpromics, she was the Chief Scientific Officer at Adjuvant Partners. She received a PhD in biochemistry, molecular biology and biophysics, with a minor in bioethics, from the University of Minnesota and completed postdoctoral work in the University of Pennsylvania Gene Therapy Program and Center for Technology Transfer with continued education in the Wharton MBA Program.

Claudio Dansky Ullmann, MD

Steve Nardi
Vice President, Manufacturing and Engineering Operations

Before joining MaxCyte, Mr. Nardi served as Vice President of Worldwide Manufacturing at Iradimed Corporation where he introduced lean manufacturing principles, and improved transparency, cost control and accountability. Prior to his work at Iradimed, Mr. Nardi was the Senior Manager of Manufacturing and Engineering at Haemonetics Corporation. He received both a BS in science, engineering and technology and an MS in technology commercialization at Northeastern University.

Claudio Dansky Ullmann, MD

Kathryn Wekselman
Vice President, Regulatory

Dr. Wekselman is a senior drug development expert with extensive experience in clinical protocol development/execution and interactions with regulatory authorities. She has 10+ years of CRO experience, and nine years at Procter & Gamble Pharmaceuticals. She earned her BSN and PhD in ​
nursing from the University of Cincinnati. She had 10 years of clinical and academic nursing experience before joining the biopharma industry. She has authored 25+ journal articles/book chapters and has presented 30+ posters, conference sessions, guest lectures and professional education seminars.

Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter

Sign Up